Literature DB >> 15934727

Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.

Michael T Spiotto1, Hans Schreiber.   

Abstract

A single tumor contains a heterogeneous population of cancer cells. Some cancer cells express antigens and are susceptible to specific CTLs. However, other cancer cells are antigen-loss variants (ALVs) that escape these CTLs because they express little or no antigen. Here, we show that antigen-specific T cells can eliminate ALVs when the parental population expresses a model gp33 antigen (KAVYNFATM) at a level sufficient to be locally cross-presented by the nonmalignant stromal cells. That is, the ALVs are eliminated as bystanders because the stroma is destroyed. ALVs escape bystander killing when the bone marrow-derived and/or non-bone marrow-derived stroma does not express the appropriate MHC or when the amount of antigen is too low for effective cross-presentation. The rapid destruction of the stroma, including bone marrow-derived as well as sessile components, and of the parental cancer cells, may be essential for the complete rejection of established tumors by preventing variant escape.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15934727

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  28 in total

1.  Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Authors:  Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Heather C Flynn Gilmer; Darlene L Knutson; Richard G Vile
Journal:  Int J Cancer       Date:  2011-11-30       Impact factor: 7.396

Review 2.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

3.  Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.

Authors:  Herbert W Kavunja; Shuyao Lang; Suttipun Sungsuwan; Zhaojun Yin; Xuefei Huang
Journal:  Cancer Immunol Immunother       Date:  2016-12-23       Impact factor: 6.968

4.  IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours.

Authors:  L-X Wang; F Talebian; J-Q Liu; M Khattabi; L Yu; X-F Bai
Journal:  Scand J Immunol       Date:  2012-03       Impact factor: 3.487

5.  Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine.

Authors:  Tu Mai; Atsushi Takano; Hiroyuki Suzuki; Takashi Hirose; Takahiro Mori; Koji Teramoto; Kazuma Kiyotani; Yusuke Nakamura; Yataro Daigo
Journal:  Oncol Lett       Date:  2017-05-05       Impact factor: 2.967

Review 6.  Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer.

Authors:  Megan Morisada; Michael Chamberlin; Clint Allen
Journal:  Head Neck       Date:  2018-02-20       Impact factor: 3.147

7.  Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts.

Authors:  Xiuying Li; Yongsheng Wang; Yuwei Zhao; Hengxiu Yang; Aiping Tong; Chengjian Zhao; Huashan Shi; Yang Li; Zhenlin Wang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

8.  Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.

Authors:  Li-Xin Wang; Suyu Shu; Mary L Disis; Gregory E Plautz
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

9.  Fas expression by tumor stroma is required for cancer eradication.

Authors:  Joanna J Listopad; Thomas Kammertoens; Kathleen Anders; Bjoern Silkenstedt; Gerald Willimsky; Karin Schmidt; Anja A Kuehl; Christoph Loddenkemper; Thomas Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

Review 10.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.